申请人:[en]SHANGHAI DEGRON BIOMEDICAL TECHNOLOGY CO., LTD.
公开号:WO2024114639A1
公开(公告)日:2024-06-06
The application relates to a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which degrades HuR, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which HuR plays a role.